Diazoxide-associated pulmonary hypertension in a patient with noncompaction cardiomyopathy. Pulm Circ 2021;11(1):2045894020987117
Date
02/23/2021Pubmed ID
33614015Pubmed Central ID
PMC7869162DOI
10.1177/2045894020987117Scopus ID
2-s2.0-85100548909 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
Development of pulmonary hypertension after initiation of diazoxide for the treatment of neonatal hyperinsulinemic hypoglycemia is a rare, but previously described association. Risk factors for development of diazoxide-associated pulmonary hypertension include lower gestational age and congenital heart disease. This novel case report describes an infant with noncompaction cardiomyopathy who developed pulmonary hypertension shortly after initiation of diazoxide for hyperinsulinemic hypoglycemia which resolved upon cessation of the drug. This case highlights the benefit of having pre-treatment knowledge of underlying cardiac anatomy and makes a case for routine echocardiographic screening for neonates initiating diazoxide treatment.
Author List
Sullivan RT, Tillman KA, Kindel SJ, Handler SSAuthors
Stephanie S. Handler MD Associate Professor in the Pediatrics department at Medical College of WisconsinSteven J. Kindel MD Associate Professor in the Pediatrics department at Medical College of Wisconsin
